Similarly, another demonstration that SCLC cells can be stimulated for an active innate immunological response was provided by Sen and colleagues, that assessed the effects of prexasertib (CHEK1 inhibitor) and olaparib (PARP inhibitor) [79]. Here, PARP1 is linked to small cell lung carcinoma.